GMAB
Price
$23.41
Change
-$0.21 (-0.89%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
14.58B
12 days until earnings call
GNMSF
Price
$225.00
Change
+$16.20 (+7.76%)
Updated
Jul 23 closing price
Capitalization
14.58B
Interact to see
Advertisement

GMAB vs GNMSF

Header iconGMAB vs GNMSF Comparison
Open Charts GMAB vs GNMSFBanner chart's image
Genmab A/S ADS
Price$23.41
Change-$0.21 (-0.89%)
Volume$13.52K
Capitalization14.58B
Genmab A/S
Price$225.00
Change+$16.20 (+7.76%)
Volume$25
Capitalization14.58B
GMAB vs GNMSF Comparison Chart in %
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. GNMSF commentary
Jul 26, 2025

To understand the difference between Genmab - ADR (GMAB) vs. Genmab (GNMSF) it is enough to know the definitions of ADR

ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (GMAB: $23.40 vs. GNMSF: $226.84)
Brand notoriety: GMAB and GNMSF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 53% vs. GNMSF: 14%
Market capitalization -- GMAB: $14.58B vs. GNMSF: $14.58B
GMAB [@Biotechnology] is valued at $14.58B. GNMSF’s [@Biotechnology] market capitalization is $14.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileGNMSF’s FA Score has 0 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • GNMSF’s FA Score: 0 green, 5 red.
According to our system of comparison, GMAB is a better buy in the long-term than GNMSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 6 TA indicator(s) are bullish while GNMSF’s TA Score has 6 bullish TA indicator(s).

  • GMAB’s TA Score: 6 bullish, 5 bearish.
  • GNMSF’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, GNMSF is a better buy in the short-term than GMAB.

Price Growth

GMAB (@Biotechnology) experienced а +6.95% price change this week, while GNMSF (@Biotechnology) price change was +4.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

GMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($14.6B) and GNMSF($14.6B) have the same market capitalization . GMAB (13.73) and GNMSF (13.31) have similar P/E ratio . GMAB YTD gains are higher at: 12.123 vs. GNMSF (9.385). GMAB (1.35B) and GNMSF (1.35B) have comparable annual earnings (EBITDA) . GMAB (3.23B) and GNMSF (3.23B) have equal amount of cash in the bank . GMAB (143M) and GNMSF (143M) have identical debt. GMAB (3.12B) and GNMSF (3.12B) have equivalent revenues.
GMABGNMSFGMAB / GNMSF
Capitalization14.6B14.6B100%
EBITDA1.35B1.35B100%
Gain YTD12.1239.385129%
P/E Ratio13.7313.31103%
Revenue3.12B3.12B100%
Total Cash3.23B3.23B100%
Total Debt143M143M100%
FUNDAMENTALS RATINGS
GMAB vs GNMSF: Fundamental Ratings
GMAB
GNMSF
OUTLOOK RATING
1..100
1991
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4141
PRICE GROWTH RATING
1..100
5253
P/E GROWTH RATING
1..100
9192
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (58) in the null industry is in the same range as GMAB (60). This means that GNMSF’s stock grew similarly to GMAB’s over the last 12 months.

GNMSF's Profit vs Risk Rating (100) in the null industry is in the same range as GMAB (100). This means that GNMSF’s stock grew similarly to GMAB’s over the last 12 months.

GNMSF's SMR Rating (41) in the null industry is in the same range as GMAB (41). This means that GNMSF’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's Price Growth Rating (52) in the null industry is in the same range as GNMSF (53). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

GMAB's P/E Growth Rating (91) in the null industry is in the same range as GNMSF (92). This means that GMAB’s stock grew similarly to GNMSF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABGNMSF
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 2 days ago
62%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
69%
Bearish Trend 4 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
66%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USSE32.780.25
+0.77%
Segall Bryant & Hamill Select Equity ETF
PBL29.920.14
+0.47%
PGIM Portfolio Ballast ETF
KEUA23.89N/A
N/A
KraneShares European Carb Allw Stgy ETF
RWO44.63-0.06
-0.13%
SPDR® Dow Jones® Global Real Estate ETF
CORX12.16-0.13
-1.06%
2x Corn ETF

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-0.97%
GNMSF - GMAB
58%
Loosely correlated
+0.82%
AXON - GMAB
47%
Loosely correlated
+3.63%
ARGX - GMAB
40%
Loosely correlated
+0.04%
ARVN - GMAB
38%
Loosely correlated
-0.63%
IMCR - GMAB
38%
Loosely correlated
-0.28%
More

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
+0.82%
GMAB - GNMSF
58%
Loosely correlated
-0.97%
RIGL - GNMSF
29%
Poorly correlated
-1.27%
ARCT - GNMSF
28%
Poorly correlated
-0.07%
ATNM - GNMSF
27%
Poorly correlated
-1.65%
AGIO - GNMSF
27%
Poorly correlated
+0.88%
More